Oryzon Genomics SA has presented preclinical efficacy data on ORY-4001, a selective histone deacetylase 6 (HDAC6) inhibitor that was recently nominated as a clinical development candidate for the treatment of certain neurological diseases such as Charcot-Marie-Tooth (CMT) disease, amyotrophic lateral sclerosis and others.